Anti-Hla-A2/Ny-Eso-1 Tcr-Transduced Autologous T Lymphocytes
Triple Negative Breast Cancer
University of Southern CaliforniaCell therapyPhase 1Active
C
37/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 28/ 100
- Competitive Position
- 65/ 100
Competitive context
183 Active assets in the Triple Negative Breast Cancer cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Carboplatin M.D. Anderson Cancer Center | Phase 4 | BB |
Cyclophosphamide M.D. Anderson Cancer Center | Phase 4 | BB |
Atezolizumab European Institute of Oncology | Phase 3 | BB |
Epirubicin M.D. Anderson Cancer Center | Phase 4 | BB |
Pembrolizumab M.D. Anderson Cancer Center | Phase 3 | BB |
View all 50 →
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →